Clinical trials: Healthy Young
Gonorrhoea
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae…
- Trial name
- NCT04722003
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Subject
HPV Vaccine Intervention for Young Sexual Minority Men
This phase III trial studies how well the Outsmart HPV intervention works in increasing HPV vaccine initiation and completion among young individuals who report having a history of same-sex partners, being sexually attracted to…
- Trial name
- NCT04032106
- Testing
- Best Practice, Informational Intervention, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 1,227 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Contraception
Investigation of Bioequivalence of Ethinylestradiol (EE) and Drospirenone (DRSP) in Two Different Tablet Formulations: Yasmin and Yasmin + Levomefolate Calcium (Metafolin) & L-5-MTHF in Two Different Tablet Formulations: Levomefolate Calcium (Metafolin) and Yasmin + Levomefolate Calcium (Metafolin)
The purpose of this study is to examine and compare the uptake of Yasmin (oral contraceptive containing drospirenone and ethinylestradiol) with or without levomefolate calcium (Metafolin, a registered vitamin supplement) in the…
- Trial name
- NCT01253174
- Testing
- EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131), EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca), L-5-MTHF Ca 0.451 mg (Metafolin)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bayer
Infections, Meningococcal
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age
The purpose of this study is to assess the immunogenicity, safety and reactogenicity of the meningococcal conjugate vaccine (MenACWY-TT) co-administered with Boostrix® versus each of the two vaccines given separately in healthy…
- Trial name
- NCT01767376
- Testing
- Meningococcal vaccine GSK134612, Boostrix®
- Where
- 15 sites in Dominican Republic, Germany and 1 more
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy, Male Infertility
HOP-2A - Intratesticular Hormone Levels
The purpose of this investigational study is to find out what hormones are present in healthy male testicles using fine needle aspiration.
- Conditions
- Healthy, Male Infertility, Prostate Disease
- Trial name
- HOP-2A (NCT00756561)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Washington
Healthy, Young Adults
Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement
The purpose of this research study is to determine the effect of number of remote limb ischemic conditioning (RLIC) cycles on enhancing learning in neurologically intact young adults.
- Trial name
- RLICC (NCT03512041)
- Testing
- RLIC - 5 cycles, RLIC - 4 Cycles, RLIC - 3 Cycles
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Chemotherapy-Induced Nausea and Vomiting
A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)
This study will assess the bioequivalence of single oral doses of aprepitant (MK0869) to a single intravenous infusion of fosaprepitant (MK0517) and also determine the effect of food on the bioavailability of oral aprepitant.
- Trial name
- NCT00945321
- Testing
- aprepitant 165 mg, Comparator: aprepitant 185 mg, Comparator: fosaprepitant 150 mg
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Sexual Behavior
Young Men and Media Study
Adolescent sexual minority males (ASMM) continue to account for a disproportionate number of HIV infections in the United States. Racial and ethnic minority populations are particularly affected.
- Trial name
- NCT04109443
- Testing
- Young Men & Media Program, Available websites on safe sex and preventing STIs
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Boston University
Healthy Young Adults
An Evaluation of the Energy Expenditure From Wii Fit Games
The purpose of this study is to provide energy expenditure data on Wii Fit / Wii Fit Plus games as compared with resting and treadmill walking/running.
- Trial name
- NCT01561716
- Testing
- Wii Fit
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Methods of Exercise in Children
Gas Exchange Kinetics and Work Load During Exercise
The purpose of this research study is to understand how different kinds of exercise affect the human body and the health of the heart and lungs.Participants will exercise in different protocols on a bicycle ergometer or…
- Trial name
- NCT03770507
- Testing
- Exercise Training
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
Modified Process Hepatitis B Vaccine in Japanese Young Adults (V232-062)
This is a study to evaluate immunogenicity, safety, and tolerability of 2XP HEPTAVAX™-II compared with the 1XP HEPTAVAX™-II in healthy Japanese young adults.
- Trial name
- NCT01463683
- Testing
- 2XP HEPTAVAX™-II SC, 1XP HEPTAVAX™-II SC, 2XP HEPTAVAX™-II IM
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
The aim of the study is to investigate the safety, tolerability, and pharmacokinetics of multiple rising doses of BI 425809 tablets given orally once daily for 12 days to young and elderly healthy male and female volunteers and…
- Trial name
- NCT02337283
- Testing
- BI 425809
- Where
- Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Epilepsy
Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites
The purpose of this study is to determine the effects of age on the pharmacokinetic profile of BIA 2-093 and its active metabolites.
- Trial name
- NCT02172755
- Testing
- BIA 2-093
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Hepatitis A
A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children
This is a study to test whether vaccination with HAVpur Junior against hepatitis A provides protection that is non-inferior to the protection afforded by vaccination with Havrix 720 Junior.
- Trial name
- NCT01349829
- Testing
- HAVpur Junior, Havrix 720 Junior
- Where
- 3 sites in India
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Meningitis, Meningococcal
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
A multicenter phase 3 safety trial in which 5,700 subjects will be assigned in a 2:1 ratio to receive 120 μg rLP2086 vaccine in a 0, 2, 6 month schedule or control.
- Trial name
- NCT01352793
- Testing
- rLP2086 vaccine, control
- Where
- 86 sites in United States, Australia and 10 more
- Volunteers
- 5,715 people, healthy volunteers welcome
- Sponsor
- Pfizer
Autonomic Nervous System Imbalance, Blood Pressure
Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators
An intervention study to assess the short-term cardiovascular effects of reducing personal air pollution exposure by wearing particulate filtering respirators.
- Conditions
- Autonomic Nervous System Imbalance, Blood Pressure, Inflammation, Vasoconstriction
- Trial name
- NCT02238028
- Testing
- Wear respirator
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fudan University
Healthy
A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
The main objectives of this trial are to investigate safety and tolerability of BI 474121 in healthy male and female young and elderly subjects following oral administration of multiple rising doses per day over 14 days.
- Trial name
- NCT04537897
- Testing
- BI 474121, Midazolam
- Where
- Germany
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00391391
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine, Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
- Where
- 19 sites in United States
- Volunteers
- 520 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
Open label, single arm, multicenter study of the shedding and safety of a single dose of trivalent, influenza virus vaccine live, intranasal in children 6 to < 60 months of age, with 28-day shedding follow-up and 180-day safety…
- Trial name
- NCT00344305
- Testing
- Trivalent influenza virus vaccine live, intranasal
- Where
- 16 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC